P.0674 Matrilysin as a potential biomarker for lithium-induced nephropathy: a serum proteomic study of two bipolar disorder cohorts

2021 ◽  
Vol 53 ◽  
pp. S494-S495
Author(s):  
A. Göteson ◽  
A. Isgren ◽  
T. Sparding ◽  
J. Holmén-Larsson ◽  
J. Jakobsson ◽  
...  
Keyword(s):  
Bipolar Disorder ◽  
Potential Biomarker ◽  
Proteomic Study

scholarly journals VGF Peptides in Cerebrospinal Fluid of Patients with Dementia with Lewy Bodies

2019 ◽  
Vol 20 (19) ◽  
pp. 4674 ◽  
Author(s):  
Inger van Steenoven ◽  
Barbara Noli ◽  
Cristina Cocco ◽  
Gian-Luca Ferri ◽  
Patrick Oeckl ◽  
...  
Keyword(s):  
Cerebrospinal Fluid ◽  
Cognitive Decline ◽  
Analytical Methods ◽  
Dementia With Lewy Bodies ◽  
Lewy Bodies ◽  
Disease Stage ◽  
Selected Reaction Monitoring ◽  
Csf Biomarkers ◽  
Potential Biomarker ◽  
Proteomic Study

In a previous proteomic study, we identified the neurosecretory protein VGF (VGF) as a potential biomarker for dementia with Lewy bodies (DLB). Here, we extended the study of VGF by comparing levels in cerebrospinal fluid (CSF) from 44 DLB patients, 20 Alzheimer’s disease (AD) patients, and 22 cognitively normal controls selected from the Amsterdam Dementia Cohort. CSF was analyzed using two orthogonal analytical methods: (1) In-house-developed quantitative ELISA and (2) selected reaction monitoring (SRM). We further addressed associations of VGF with other CSF biomarkers and cognition. VGF levels were lower in CSF from patients with DLB compared to either AD patients or controls. VGF was positively correlated with CSF tau and α-synuclein (0.55 < r < 0.75), but not with Aβ1-42. In DLB patients, low VGF levels were related to a more advanced cognitive decline at time of first presentation, whereas high levels of VGF were associated with steeper subsequent longitudinal cognitive decline. Hence, CSF VGF levels were lower in DLB compared to both AD and controls across different analytical methods. The strong associations with cognitive decline further points out VGF as a possible disease stage or prognostic marker for DLB.

Brain-Derived Neurotrophic Factor (Bdnf) and Gray Matter Volume in Bipolar Disorder

2016 ◽  
Vol 40 ◽  
pp. 33-37 ◽  
Author(s):  
S. Poletti ◽  
V. Aggio ◽  
T.A. Hoogenboezem ◽  
O. Ambrée ◽  
H. de Wit ◽  
...  
Keyword(s):  
Bipolar Disorder ◽  
Neurotrophic Factor ◽  
Interaction Analysis ◽  
Lithium Treatment ◽  
Gray Matter Volume ◽  
Brain Derived Neurotrophic Factor ◽  
Anterior Cingulate ◽  
Parahippocampal Gyrus ◽  
Type I ◽  
Potential Biomarker

AbstractIntroductionBipolar Disorder (BD) is a severe psychiatric condition characterized by grey matter (GM) volumes reduction. Neurotrophic factors have been suggested to play a role in the neuroprogressive changes during the illness course. In particular peripheral brain-derived neurotrophic factor (BDNF) has been proposed as a potential biomarker related to disease activity and neuroprogression in BD. The aim of our study was to investigate if serum levels of BDNF are associated with GM volumes in BD patients and healthy controls (HC).MethodsWe studied 36 inpatients affected by a major depressive episode in course of BD type I and 17 HC. Analysis of variance was performed to investigate the effect of diagnosis on GM volumes in the whole brain. Threshold for significance was P < 0.05, Family Wise Error (FWE) corrected for multiple comparisons. All the analyses were controlled for the effect of nuisance covariates known to influence GM volumes, such as age, gender and lithium treatment.ResultsBD patients showed significantly higher serum BDNF levels compared with HC. Reduced GM volumes in BD patients compared to HC were observed in several brain areas, encompassing the caudate head, superior temporal gyrus, insula, fusiform gyrus, parahippocampal gyrus, and anterior cingulate cortex. The interaction analysis between BDNF levels and diagnosis showed a significant effect in the middle frontal gyrus. HC reported higher BDNF levels associated with higher GM volumes, whereas no association between BDNF and GM volumes was observed in BD.DiscussionOur study seems to suggest that although the production of BDNF is increased in BD possibly to prevent and repair neural damage, its effects could be hampered by underlying neuroinflammatory processes interfering with the neurodevelopmental role of BDNF.

Evidence towards RNA Binding Motif (RNP1, RRM) Protein 3 (RBM3) as a Potential Biomarker of Lithium Response in Bipolar Disorder Patients

2017 ◽  
Vol 62 (3-4) ◽  
pp. 304-308 ◽  
Author(s):  
Eleni Merkouri Papadima ◽  
Paola Niola ◽  
Carla Melis ◽  
Claudia Pisanu ◽  
Donatella Congiu ◽  
...  
Keyword(s):  
Bipolar Disorder ◽  
Rna Binding ◽  
Binding Motif ◽  
Potential Biomarker ◽  
Lithium Response

scholarly journals Identification of lncRNA NR_028138.1 as a biomarker and construction of a ceRNA network for bipolar disorder

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Ling He ◽  
Pengtao Zou ◽  
Wanlei Sun ◽  
Yonghui Fu ◽  
Wenfeng He ◽  
...  
Keyword(s):  
Bipolar Disorder ◽  
Roc Curve ◽  
Regulatory Network ◽  
Noncoding Rnas ◽  
Differentially Expressed ◽  
Diagnostic Model ◽  
Network Analyses ◽  
Control Subjects ◽  
Cerna Network ◽  
Potential Biomarker

AbstractThe pathogenesis of bipolar disorder (BD), a chronic mood disorder, is largely unknown. Noncoding RNAs play important roles in the pathogenesis of BD. However, little is known about the correlations of long noncoding RNAs (lncRNAs) with BD. Illumina high-throughput sequencing in BD patients and normal controls was used to identify differentially expressed (DE) genes. Two-step real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) was used to validate DE-RNAs in the first cohort (50 BD and 50 control subjects). Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways and lncRNA-mRNA coexpression and lncRNA-microRNA (miRNA)-messenger RNA (mRNA) competing endogenous RNA (ceRNA) network analyses were used to predict the functions of DE-RNAs. Receiver operating characteristic (ROC) curve analysis and logistic regression were applied to evaluate diagnostic performance in an additional testing group (80 BD and 66 control subjects). A total of 576 significantly DE-lncRNAs and 262 DE-mRNAs were identified in BD patients, and 95 lncRNA-miRNA-mRNA interactions were used to construct a ceRNA regulatory network. Analysis of the first cohort showed that six RNAs (NR_028138.1, TCONS_00018621, TCONS_00002186, TNF, PID1, and SDK1) were differentially expressed in the BD group (P < 0.01). NR_028138.1 was used to establish a BD diagnostic model (area under the ROC curve 0.923, P < 0.004, 95% CI: 0.830–0.999). Verification in the second cohort revealed uniformly significant differences in NR_028138.1 (P < 0.0001). This study constructed a ceRNA regulatory network and provided a hypothesis for the pathogenesis of BD. NR_028138.1 was identified as a central element involved in the transcriptional regulation in BD and a potential biomarker.

scholarly journals The role of oxidative stress in bipolar disorder: Is DNA damage a potential biomarker of disease severity?

2016 ◽  
Vol 10 ◽  
Author(s):  
Chan Lai Fong ◽  
Loo Jiann Lin ◽  
Goon Jo Ann ◽  
Mohamad Kamal Nurul Ain ◽  
Damanhuri Hanafi ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Bipolar Disorder ◽  
Dna Damage ◽  
Disease Severity ◽  
Potential Biomarker

scholarly journals Increased Global-Brain Functional Connectivity Is Associated with Dyslipidemia and Cognitive Impairment in First-Episode, Drug-Naive Patients with Bipolar Disorder

2021 ◽  
Vol 2021 ◽  
pp. 1-10
Author(s):  
Pan Pan ◽  
Yan Qiu ◽  
Ziwei Teng ◽  
Sujuan Li ◽  
Jing Huang ◽  
...  
Keyword(s):  
Bipolar Disorder ◽  
Cognitive Impairment ◽  
Functional Connectivity ◽  
Inferior Frontal Gyrus ◽  
First Episode ◽  
Support Vector ◽  
Potential Biomarker ◽  
Drug Naïve ◽  
Pars Triangularis ◽  
Global Brain

Objectives. Previous researches have demonstrated that abnormal functional connectivity (FC) is associated with the pathophysiology of bipolar disorder (BD). However, inconsistent results were obtained due to different selections of regions of interest in previous researches. This study is aimed at examining voxel-wise brain-wide functional connectivity (FC) alterations in the first-episode, drug-naive patient with BD in an unbiased way. Methods. A total of 35 patients with BD and 37 age-, sex-, and education-matched healthy controls underwent resting-state functional magnetic resonance imaging (rs-fMRI). Global-brain FC (GFC) was applied to analyze the image data. Support vector machine (SVM) was adopted to probe whether GFC abnormalities could be used to identify the patients from the controls. Results. Patients with BD exhibited increased GFC in the left inferior frontal gyrus (LIFG), pars triangularis and left precuneus (PCu)/superior occipital gyrus (SOG). The left PCu belongs to the default mode network (DMN). Furthermore, increased GFC in the LIFG, pars triangularis was positively correlated with the triglycerides (TG) and low-density lipoprotein cholesterol (LDL-C) and negatively correlated with the scores of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) coding test and Stroop color. Increased GFC values in the left PCu/SOG can be applied to discriminate patients from controls with preferable sensitivity (80.00%), specificity (75.68%), and accuracy (77.78%). Conclusions. This study found increased GFC in the brain regions of DMN; LIFG, pars triangularis; and LSOG, which was associated with dyslipidemia and cognitive impairment in patients with BD. Moreover, increased GFC values in the left PCu/SOG may be utilized as a potential biomarker to differentiate patients with BD from controls.

Significant increasing of DISC2 long non-coding RNA expression as a potential biomarker in bipolar disorder

2019 ◽  
Vol 696 ◽  
pp. 206-211 ◽  
Author(s):  
Bahar Naghavi-Gargari ◽  
Alireza Zahirodin ◽  
Sayyed Mohammad Hossein Ghaderian ◽  
Zeinab Shirvani-Farsani
Keyword(s):  
Bipolar Disorder ◽  
Rna Expression ◽  
Non Coding Rna ◽  
Potential Biomarker ◽  
Long Non Coding Rna

scholarly journals A novel Trypanosoma cruzi secreted antigen as a potential biomarker of Chagas disease

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Rana Nagarkatti ◽  
David Acosta ◽  
Nirmallya Acharyya ◽  
Fernanda Fortes de Araujo ◽  
Silvana Maria Elói-Santos ◽  
...  
Keyword(s):  
Chagas Disease ◽  
Treatment Efficacy ◽  
Clinical Symptoms ◽  
Chronic Phase ◽  
Hypothetical Protein ◽  
Life Cycle Stages ◽  
Potential Biomarker ◽  
Before And After ◽  
Proteomic Study ◽  
Secreted Antigens

Abstract Chagas drug discovery has been hampered by a lack of validated assays to establish treatment efficacy in pre-clinical animal models and in patients infected with T. cruzi. Reduced levels of parasite secreted antigens in the blood of infected hosts could be used to demonstrate treatment efficacy. A published proteomic study of parasite secreted antigens identified the hypothetical protein Tc_5171 as a secreted antigen. In this report, we developed Tc_5171 specific antibodies and showed that the native protein was expressed by the three life cycle stages of the parasite. Anti-peptide antibodies were able to detect the parasite antigen in blood of infected mice during the acute and the chronic phase of infection. Benznidazole treatment of infected mice significantly reduced their blood antigen levels. Of clinical significance, patients diagnosed with Chagas disease, either asymptomatic or with cardiac clinical symptoms had significantly higher Tc_5171 antigen levels compared to endemic controls. Pair-wise analysis, before and after Benznidazole treatment, of patients with asymptomatic Chagas disease showed a significant reduction in antigen levels post treatment. Taken together, our results indicate that Tc_5171 could be used as a novel biomarker of Chagas disease for diagnosis and to assess treatment efficacy.

scholarly journals Homocysteine as a peripheral biomarker in bipolar disorder: A meta-analysis

2017 ◽  
Vol 43 ◽  
pp. 81-91 ◽  
Author(s):  
E. Salagre ◽  
A.F. Vizuete ◽  
M. Leite ◽  
D.J. Brownstein ◽  
A. McGuinness ◽  
...  
Keyword(s):  
Bipolar Disorder ◽  
Carbon Metabolism ◽  
Meta Analysis ◽  
Healthy Controls ◽  
Large Effect Size ◽  
Cross Sectional ◽  
Potential Biomarker ◽  
Cross Sectional Studies ◽  
Meta Analyses ◽  
The Relationship

AbstractBackground:Bipolar disorder (BD) is a psychiatric disorder with an uncertain aetiology. Recently, special attention has been given to homocysteine (Hcy), as it has been suggested that alterations in 1-carbon metabolism might be implicated in diverse psychiatric disorders. However, there is uncertainty regarding possible alterations in peripheral Hcy levels in BD.Methods:This study comprises a meta-analysis comparing serum and plasma Hcy levels in persons with BD and healthy controls. We conducted a systematic search for all eligible English and non-English peer-reviewed articles.Results:Nine cross-sectional studies were included in the meta-analyses, providing data on 1547 participants. Random-effects meta-analysis showed that serum and plasma levels of Hcy were increased in subjects with BD in either mania or euthymia when compared to healthy controls, with a large effect size in the mania group (g= 0.98, 95% CI: 0.8–1.17,P< 0.001,n= 495) and a small effect in the euthymia group (g= 0.3, 95% CI: 0.11–0.48,P= 0.002,n= 1052).Conclusions:Our meta-analysis provides evidence that Hcy levels are elevated in persons with BD during mania and euthymia. Peripheral Hcy could be considered as a potential biomarker in BD, both of trait (since it is increased in euthymia), and also of state (since its increase is more accentuated in mania). Longitudinal studies are needed to clarify the relationship between bipolar disorder and Hcy, as well as the usefulness of peripheral Hcy as both a trait and state biomarker in BD.

Sign in / Sign up

Export Citation Format

Share Document